ArticleHerzschrittmachertherapie & Elektrophysiologie2025
[Modular heart rhythm management : EMPOWER™ leadless pacemaker as an add-on to the EMBLEM™ S-ICD].
Article in Herzschrittmachertherapie & Elektrophysiologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technological advances in medicine now enable wireless antibradycardia myocardial stimulation. Leadless pacemakers (LP) have already been introduced by Abbott (Abbott Park, IL, USA; Nanostim™, Aveir™), Medtronic (Minneapolis, MN, USA; Micra AV/VR™), and most recently by Boston Scientific (Marlborough, MA, USA; EMPOWER™). Although case reports have been published using different LP in combination with the EMBLEM™ S‑ICD, only the EMPOWER™ LP provides the technological prerequisites for modular cardiac rhythm management (mCRM). In this modular system, an ATP command can be transmitted from the S‑ICD to the LP when required, potentially reducing the number of S‑ICD shocks. Additionally, long-term antibradycardia pacing can be reliably ensured. Following extensive preclinical studies, the 6‑month results of the first prospective multicenter study (MODULAR-ATP) are now available, analyzing the safety, performance, and necessity of the mCRM system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.